Skip to main content
TipRanks
Go Ultimate75% OFF

Denali Therapeutics (DNLI) Stock Statistics & Valuation Metrics

895 Followers

Total Valuation

Denali Therapeutics has a market cap or net worth of $3.00B. The enterprise value is $3.49B.

Market Cap
$3.00B
Enterprise Value
$3.49B

Share Statistics

Denali Therapeutics has 160,290,540 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
160,290,540
Owned by Insiders
5.12%
Owned by Institutions
76.59%

Financial Efficiency

Denali Therapeutics’s return on equity (ROE) is -0.51 and return on invested capital (ROIC) is -52.59%.

Return on Equity (ROE)
-0.51
Return on Assets (ROA)
-0.45
Return on Invested Capital (ROIC)
-52.59%
Return on Capital Employed (ROCE)
-0.53
Revenue Per Employee
0
Profits Per Employee
-1.02M
Employee Count
503
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Denali Therapeutics is -10.83. Denali Therapeutics’s PEG ratio is -0.26.

PE Ratio
-10.83
PS Ratio
140.48
PB Ratio
3.81
Price to FCF
-6.68
Price to Operating Cash Flow
-7.95
PEG Ratio
-0.26

Income Statement

In the last 12 months, Denali Therapeutics had revenue of 0 and earned -512.54M in profits. Earnings per share was -2.97.

Revenue
0
Gross Profit
-11.18M
Operating Income
-555.34M
Pretax Income
-512.44M
Net Income
-512.54M
EBITDA
-497.63M
Earnings Per Share (EPS)
-2.97

Cash Flow

In the last 12 months, operating cash flow was -444.19M and capital expenditures -5.80M, giving a free cash flow of -449.99M billion.

Operating Cash Flow
-444.19M
Free Cash Flow
-449.99M
Free Cash Flow per Share
-2.39

Dividends & Yields

Denali Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-14.98%
Earnings Yield
-8.91%

Stock Price Statistics

Beta
1.71
52-Week Price Change
9.27%
50-Day Moving Average
19.84
200-Day Moving Average
21.24
Relative Strength Index (RSI)
43.53
Average Volume (3m)
1.62M

Important Dates

Denali Therapeutics upcoming earnings date is Mar 01, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 03, 2026
Next Earnings Date
Mar 01, 2027
Ex-Dividend Date
―

Financial Position

Denali Therapeutics as a current ratio of 9.16, with Debt / Equity ratio of 3.63%

Current Ratio
9.16
Quick Ratio
9.16
Debt to Market Cap
0.00
Net Debt to EBITDA
0.34
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Denali Therapeutics has paid 102.00K in taxes.

Income Tax
102.00K
Effective Tax Rate
-0.00

Enterprise Valuation

Denali Therapeutics EV to EBITDA ratio is -10.44, with an EV/FCF ratio of -6.99.

EV to Sales
147.13
EV to EBITDA
-10.44
EV to Free Cash Flow
-6.99
EV to Operating Cash Flow
-7.08

Balance Sheet

Denali Therapeutics has $516.20M in cash and marketable securities with $244.90M in debt, giving a net cash position of $271.29M billion.

Cash & Marketable Securities
$516.20M
Total Debt
$244.90M
Net Cash
$271.29M
Net Cash Per Share
$1.69
Tangible Book Value Per Share
$4.73

Margins

Gross margin is 71.96%, with operating margin of -2488.14%, and net profit margin of -1470.50%.

Gross Margin
71.96%
Operating Margin
-2488.14%
Pretax Margin
-1470.03%
Net Profit Margin
-1470.50%
EBITDA Margin
-1409.91%
EBIT Margin
-1470.03%

Analyst Forecast

The average price target for Denali Therapeutics is $35.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$35.33
Price Target Upside
88.55% Upside
Analyst Consensus
Strong Buy
Analyst Count
8
Revenue Growth Forecast
―
EPS Growth Forecast
40.59%

Scores

Smart Score
4
AI Score
60